No increased risk of major adverse cardiac events found with lorcaserin
Results from a 12,000 patient post-marketing safety study mandated by the US Food and Drug Administration (FDA) show that lorcaserin, the obesity drug does not increase the risk of any major adverse cardiac events (MACE), which included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies